X

Trial Profile

Effects of Long-term Dapagliflozin Treatment on Hemorheology, Leukocyte Activation and Oxidative Stress

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary) ; Antihyperglycaemics
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms D-PATH

Most Recent Events

16 Jun 2020 Results assessing effect of long-term Dapagliflozin treatment on hemorheology presented at the 80th Annual Scientific Sessions of the American Diabetes Association
24 Jul 2019 Planned End Date changed from 22 Mar 2019 to 20 Mar 2019.
21 Dec 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com